Taxoids: cancer-fighting compounds from nature

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• The diterpenoid taxane skeleton is a foundational structure for numerous anticancer agents.
• Paclitaxel (Taxol) has been clinically approved for over a decade.
• Ongoing research explores taxane derivatives for improved therapeutic profiles.

Purpose of the Study:

• To review advancements in the discovery and development of taxane-based anticancer agents.
• To highlight the continued relevance of the taxane scaffold in drug design.
• To explore emerging non-oncological applications of taxanes.

Main Methods:

• Literature review of preclinical and clinical studies on taxane derivatives.
• Analysis of pharmacological and toxicological data for novel taxane compounds.
• Examination of recent research on paclitaxel's broader therapeutic uses.

Main Results:

• The taxane skeleton continues to serve as a versatile scaffold for new anticancer drug discovery.
• Paclitaxel demonstrates potential as a 'tunable' therapeutic agent.
• Paclitaxel exhibits efficacy beyond cancer treatment, including in cardiovascular applications (e.g., coated stents).

Conclusions:

• The taxane scaffold remains a valuable platform for developing next-generation anticancer therapies.
• Paclitaxel's unique properties and diverse applications underscore its significance in medicine.
• Further research into taxane derivatives may yield novel treatments for various diseases.